Hemoperfusion in Poisoning and Drug Overdose.
Hemoperfusion (HP) is an extracorporeal blood purification therapy that is used to remove poisons or drugs from the body. This chapter provides a brief overview of the technical aspects and the potent...
Syndrome des mouvements périodiques nocturnes des membres : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostique-t-on ce syndrome ?
Le diagnostic repose sur l'observation des mouvements nocturnes et des études du sommeil.
#2
Quels tests sont utilisés pour le diagnostic ?
La polysomnographie est le test principal pour évaluer les mouvements et les cycles de sommeil.
#3
Quels critères sont utilisés pour le diagnostic ?
Les critères incluent la fréquence des mouvements et leur impact sur la qualité du sommeil.
#4
Le syndrome est-il confondu avec d'autres troubles ?
Oui, il peut être confondu avec le syndrome des jambes sans repos ou d'autres troubles du sommeil.
#5
Les antécédents médicaux influencent-ils le diagnostic ?
Oui, des antécédents de troubles du sommeil ou neurologiques peuvent influencer le diagnostic.
Symptômes 5
#1
Quels sont les symptômes principaux ?
Les symptômes incluent des mouvements involontaires des membres et des réveils fréquents.
#2
Les mouvements se produisent-ils à des moments précis ?
Oui, ils se produisent généralement pendant les phases de sommeil léger.
#3
Y a-t-il des douleurs associées aux mouvements ?
Les mouvements peuvent causer des douleurs ou de l'inconfort, perturbant le sommeil.
#4
Les symptômes varient-ils d'une personne à l'autre ?
Oui, l'intensité et la fréquence des mouvements peuvent varier considérablement.
#5
Les symptômes affectent-ils la qualité de vie ?
Oui, ils peuvent entraîner une fatigue diurne et affecter la qualité de vie globale.
Prévention 5
#1
Peut-on prévenir ce syndrome ?
Il n'existe pas de méthode de prévention garantie, mais une bonne hygiène du sommeil peut aider.
#2
Le stress influence-t-il le syndrome ?
Oui, le stress peut aggraver les symptômes, donc la gestion du stress est conseillée.
#3
L'alimentation joue-t-elle un rôle ?
Une alimentation équilibrée peut contribuer à un meilleur sommeil et réduire les symptômes.
#4
L'exercice physique aide-t-il ?
Oui, l'exercice régulier peut améliorer la qualité du sommeil et réduire les mouvements nocturnes.
#5
Les habitudes de sommeil influencent-elles le syndrome ?
Oui, des habitudes de sommeil régulières peuvent aider à réduire l'incidence des mouvements.
Traitements 5
#1
Quels traitements sont disponibles ?
Les traitements incluent des médicaments comme les benzodiazépines et des thérapies comportementales.
#2
Les changements de mode de vie aident-ils ?
Oui, des changements comme une meilleure hygiène du sommeil peuvent réduire les symptômes.
#3
Les médicaments sont-ils toujours nécessaires ?
Pas toujours, certains patients peuvent gérer les symptômes avec des approches non médicamenteuses.
#4
Y a-t-il des effets secondaires aux traitements ?
Oui, certains médicaments peuvent provoquer des effets secondaires comme la somnolence.
#5
Les traitements sont-ils efficaces à long terme ?
L'efficacité peut varier, et un suivi régulier est souvent nécessaire pour ajuster le traitement.
Complications 5
#1
Quelles complications peuvent survenir ?
Les complications incluent la fatigue chronique et des troubles de l'humeur comme l'anxiété.
#2
Le syndrome peut-il affecter la santé mentale ?
Oui, les troubles du sommeil peuvent contribuer à des problèmes de santé mentale.
#3
Y a-t-il un risque accru d'autres maladies ?
Oui, les troubles du sommeil peuvent augmenter le risque de maladies cardiovasculaires.
#4
Les complications sont-elles réversibles ?
Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie.
#5
Comment les complications sont-elles gérées ?
La gestion des complications implique souvent une approche multidisciplinaire incluant médecins et psychologues.
Facteurs de risque 5
#1
Quels sont les facteurs de risque connus ?
Les facteurs incluent l'âge avancé, des troubles neurologiques et des antécédents familiaux.
#2
Le sexe influence-t-il le risque ?
Oui, les hommes sont souvent plus touchés que les femmes par ce syndrome.
#3
Les troubles du sommeil augmentent-ils le risque ?
Oui, des troubles comme l'apnée du sommeil peuvent augmenter le risque de ce syndrome.
#4
Les médicaments peuvent-ils être un facteur de risque ?
Oui, certains médicaments, comme les antidépresseurs, peuvent exacerber les symptômes.
#5
Le mode de vie influence-t-il le risque ?
Oui, un mode de vie sédentaire et une mauvaise hygiène du sommeil peuvent augmenter le risque.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/02/2025
Contenu vérifié selon les dernières recommandations médicales
Auteurs principaux
Sterre van der Veen
3 publications dans cette catégorie
Affiliations :
- Pontificia Universidad Católica Argentina (UCA) Buenos Aires Argentina.
- Department of Neurology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Myoclonus-Ataxia Syndromes: A Diagnostic Approach.
Movement disorders clinical practice 2020-11-03
-
Negative Myoclonus: Neurophysiological Study and Clinical Impact in Progressive Myoclonus Ataxia.
Movement disorders : official journal of the Movement Disorder Society 2024-02-22
-
Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes.
Parkinsonism & related disorders 2019-10-22
Marina A J Tijssen
3 publications dans cette catégorie
Affiliations :
- Department of Neurology University of Groningen, University Medical Center Groningen Groningen The Netherlands.
- Expertise Center Movement Disorders Groningen University Medical Center Groningen (UMCG) Groningen The Netherlands.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Myoclonus-Ataxia Syndromes: A Diagnostic Approach.
Movement disorders clinical practice 2020-11-03
-
Negative Myoclonus: Neurophysiological Study and Clinical Impact in Progressive Myoclonus Ataxia.
Movement disorders : official journal of the Movement Disorder Society 2024-02-22
-
Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes.
Parkinsonism & related disorders 2019-10-22
Matthew R Epstein
3 publications dans cette catégorie
Affiliations :
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, New York.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Prevalence of the nocturnal polyuria syndrome in men.
Neurourology and urodynamics 2020-06-05
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
Kyle P Michelson
3 publications dans cette catégorie
Affiliations :
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, New York.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Prevalence of the nocturnal polyuria syndrome in men.
Neurourology and urodynamics 2020-06-05
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
Thomas F Monaghan
3 publications dans cette catégorie
Affiliations :
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, New York.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Prevalence of the nocturnal polyuria syndrome in men.
Neurourology and urodynamics 2020-06-05
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
Jeffrey P Weiss
3 publications dans cette catégorie
Affiliations :
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, New York.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Prevalence of the nocturnal polyuria syndrome in men.
Neurourology and urodynamics 2020-06-05
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
E Ann Yeh
3 publications dans cette catégorie
Affiliations :
- Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada.
- Department of Neurosciences and Mental Health, SickKids Research Institute, Toronto, Canada.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome.
Pediatric blood & cancer 2019-04-29
-
Brain Volumes in Opsoclonus-Myoclonus Ataxia Syndrome: A Longitudinal Study.
Journal of child neurology 2024-03-27
-
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
Neurology(R) neuroimmunology & neuroinflammation 2022-03-08
Mark P Gorman
3 publications dans cette catégorie
Affiliations :
- From the Children's Neurosciences (T.R., M.L.), Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre; Department Women and Children's Health (T.R., M.L.), School of Life Course Sciences (SoLCS), King's College London, UK; Division of Neurology (E.A.Y.), Department of Pediatrics, Neurosciences and Mental Health (RI), The Hospital for Sick Children; Faculty of Medicine (E.A.Y.), The University of Toronto, Ontario, Canada; Department of Pediatrics (Y.K.) and Department of Neurology (Y.K.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics (Y.K.), Weill Medical College of Cornell University, New York; Children and Young People's Unit (Paola Angelini), The Royal Marsden, Downs Road, Sutton, Surrey; UCL Great Ormond Street Institute of Child Health (C.H.), Department of Neurology, Great Ormond Street Hospital for Children, London; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; SiRIC RTOP (G.S.), Translational Research Department, PSL Research University, Institut Curie Research Center; INSERM U830 (G.S.), PSL Research University, Institut Curie Research Center; SIREDO Center: Care (G.S.), Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Department of Child and Adolescent Psychiatry (P.S.), King's College London; Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD) Research Team (P.S.), South London and Maudsley NHS Foundation Trust, London, UK; Baylor College of Medicine (T.L.), Texas Children's Hospital, Houston; Kids Neuroscience Centre (R.C.D.), The Children's Hospital at Westmead, Westmead, NSW, Australia; TY Nelson Department of Neurology and Neurosurgery (R.C.D.), The Children's Hospital at Westmead; The Children's Hospital at Westmead Clinical School (R.C.D.), Faculty of Medicine, University of Sydney, NSW, Australia; Pediatric Neurology Department (K.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Saclay, Bicêtre Hospital; National Referral Center for Rare Inflammatory and Auto-Immune Brain and Spinal Diseases (K.D.); Inserm UMR 1184 (K.D.), Immunology of Viral Infections and Autoimmune Diseases, CEA, IDMIT, Le Kremlin Bicêtre, France; Department of Pediatric Hematology and Oncology (B.H.), University Children's Hospital, Koln; Division of Child Neurology (A.K.), University Children's Hospital Bern Inselspital, University of Bern; Department of Pediatric Neurology (A.K.), University Children's Hospital Basel, Switzerland; Department of Pediatrics (Pedro de Alarcon), University of Illinois College of Medicine at Peoria, Peoria IL; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard Medical School, MA; Division of Neurology (W.G.M.), Department of Pediatrics, Children's Hospital Los Angeles; and Department of Neurology (W.G.M.), Keck School of Medicine at the University of Southern California, Los Angeles.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
Neurology(R) neuroimmunology & neuroinflammation 2022-03-08
-
Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome.
Neurology(R) neuroimmunology & neuroinflammation 2021-09-02
-
IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study.
Developmental medicine and child neurology 2020-07-22
Hideaki Shiraishi
2 publications dans cette catégorie
Affiliations :
- Department of Pediatrics, Hokkaido University Hospital, Japan. Electronic address: siraisi@med.hokudai.ac.jp.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Perampanel for nonepileptic myoclonus in Angelman syndrome.
Brain & development 2020-03-10
-
Neuroblastoma-related severe hypoperfusion in the cerebellum of an infant: A case of opsoclonus-myoclonus syndrome.
Asia Oceania journal of nuclear medicine & biology
Russell C Dale
2 publications dans cette catégorie
Affiliations :
- Kids Neuroscience Centre, Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Opsoclonus-myoclonus in Aicardi-Goutières syndrome.
Developmental medicine and child neurology 2021-06-21
-
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
Neurology(R) neuroimmunology & neuroinflammation 2022-03-08
Y Lin
2 publications dans cette catégorie
Affiliations :
- Department of Neurology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
[Clinical analysis of adult oculomoclonus-myoclonus syndrome with vertigo].
Zhonghua nei ke za zhi
Donald L Bliwise
2 publications dans cette catégorie
Affiliations :
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
Zhan D Wu
2 publications dans cette catégorie
Affiliations :
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, New York.
- Department of Urology, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
Karel Everaert
2 publications dans cette catégorie
Affiliations :
- Department of Urology, Ghent University Hospital, Ghent, Belgium.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome.
Neurourology and urodynamics 2020-01-21
-
Differential Nocturnal Diuresis Rates Among Patients with and Without Nocturnal Polyuria Syndrome.
European urology focus 2018-11-02
Carmen Yea
2 publications dans cette catégorie
Affiliations :
- Department of Neurosciences and Mental Health, SickKids Research Institute, Toronto, Canada.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome.
Pediatric blood & cancer 2019-04-29
-
Brain Volumes in Opsoclonus-Myoclonus Ataxia Syndrome: A Longitudinal Study.
Journal of child neurology 2024-03-27
Ming Lim
2 publications dans cette catégorie
Affiliations :
- Children's Neuroscience Centre, Evelina London Children's Hospital, Guy's and St Thomas' NHS Trust, London SE1 7EH, UK.
- Department of Women and Children's Health, Faculty of Life Sciences, King's College, London SE1 7EH, UK.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Evolving Cognitive Dysfunction in Children with Neurologically Stable Opsoclonus-Myoclonus Syndrome.
Children (Basel, Switzerland) 2020-08-19
-
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
Neurology(R) neuroimmunology & neuroinflammation 2022-03-08
Mark Hallett
2 publications dans cette catégorie
Affiliations :
- Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
KCNN2 Mutation in Pediatric Tremor Myoclonus Dystonia Syndrome with Electrophysiological Evaluation.
Tremor and other hyperkinetic movements (New York, N.Y.) 2022-01-24
-
Myoclonus: An Electrophysiological Diagnosis.
Movement disorders clinical practice 2020-06-17
Andrea Klein
2 publications dans cette catégorie
Affiliations :
- From the Children's Neurosciences (T.R., M.L.), Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre; Department Women and Children's Health (T.R., M.L.), School of Life Course Sciences (SoLCS), King's College London, UK; Division of Neurology (E.A.Y.), Department of Pediatrics, Neurosciences and Mental Health (RI), The Hospital for Sick Children; Faculty of Medicine (E.A.Y.), The University of Toronto, Ontario, Canada; Department of Pediatrics (Y.K.) and Department of Neurology (Y.K.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics (Y.K.), Weill Medical College of Cornell University, New York; Children and Young People's Unit (Paola Angelini), The Royal Marsden, Downs Road, Sutton, Surrey; UCL Great Ormond Street Institute of Child Health (C.H.), Department of Neurology, Great Ormond Street Hospital for Children, London; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; SiRIC RTOP (G.S.), Translational Research Department, PSL Research University, Institut Curie Research Center; INSERM U830 (G.S.), PSL Research University, Institut Curie Research Center; SIREDO Center: Care (G.S.), Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Department of Child and Adolescent Psychiatry (P.S.), King's College London; Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD) Research Team (P.S.), South London and Maudsley NHS Foundation Trust, London, UK; Baylor College of Medicine (T.L.), Texas Children's Hospital, Houston; Kids Neuroscience Centre (R.C.D.), The Children's Hospital at Westmead, Westmead, NSW, Australia; TY Nelson Department of Neurology and Neurosurgery (R.C.D.), The Children's Hospital at Westmead; The Children's Hospital at Westmead Clinical School (R.C.D.), Faculty of Medicine, University of Sydney, NSW, Australia; Pediatric Neurology Department (K.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Saclay, Bicêtre Hospital; National Referral Center for Rare Inflammatory and Auto-Immune Brain and Spinal Diseases (K.D.); Inserm UMR 1184 (K.D.), Immunology of Viral Infections and Autoimmune Diseases, CEA, IDMIT, Le Kremlin Bicêtre, France; Department of Pediatric Hematology and Oncology (B.H.), University Children's Hospital, Koln; Division of Child Neurology (A.K.), University Children's Hospital Bern Inselspital, University of Bern; Department of Pediatric Neurology (A.K.), University Children's Hospital Basel, Switzerland; Department of Pediatrics (Pedro de Alarcon), University of Illinois College of Medicine at Peoria, Peoria IL; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard Medical School, MA; Division of Neurology (W.G.M.), Department of Pediatrics, Children's Hospital Los Angeles; and Department of Neurology (W.G.M.), Keck School of Medicine at the University of Southern California, Los Angeles.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
Neurology(R) neuroimmunology & neuroinflammation 2022-03-08
-
IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study.
Developmental medicine and child neurology 2020-07-22
Wendy G Mitchell
2 publications dans cette catégorie
Affiliations :
- From the Children's Neurosciences (T.R., M.L.), Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre; Department Women and Children's Health (T.R., M.L.), School of Life Course Sciences (SoLCS), King's College London, UK; Division of Neurology (E.A.Y.), Department of Pediatrics, Neurosciences and Mental Health (RI), The Hospital for Sick Children; Faculty of Medicine (E.A.Y.), The University of Toronto, Ontario, Canada; Department of Pediatrics (Y.K.) and Department of Neurology (Y.K.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics (Y.K.), Weill Medical College of Cornell University, New York; Children and Young People's Unit (Paola Angelini), The Royal Marsden, Downs Road, Sutton, Surrey; UCL Great Ormond Street Institute of Child Health (C.H.), Department of Neurology, Great Ormond Street Hospital for Children, London; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; SiRIC RTOP (G.S.), Translational Research Department, PSL Research University, Institut Curie Research Center; INSERM U830 (G.S.), PSL Research University, Institut Curie Research Center; SIREDO Center: Care (G.S.), Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Department of Child and Adolescent Psychiatry (P.S.), King's College London; Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD) Research Team (P.S.), South London and Maudsley NHS Foundation Trust, London, UK; Baylor College of Medicine (T.L.), Texas Children's Hospital, Houston; Kids Neuroscience Centre (R.C.D.), The Children's Hospital at Westmead, Westmead, NSW, Australia; TY Nelson Department of Neurology and Neurosurgery (R.C.D.), The Children's Hospital at Westmead; The Children's Hospital at Westmead Clinical School (R.C.D.), Faculty of Medicine, University of Sydney, NSW, Australia; Pediatric Neurology Department (K.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Saclay, Bicêtre Hospital; National Referral Center for Rare Inflammatory and Auto-Immune Brain and Spinal Diseases (K.D.); Inserm UMR 1184 (K.D.), Immunology of Viral Infections and Autoimmune Diseases, CEA, IDMIT, Le Kremlin Bicêtre, France; Department of Pediatric Hematology and Oncology (B.H.), University Children's Hospital, Koln; Division of Child Neurology (A.K.), University Children's Hospital Bern Inselspital, University of Bern; Department of Pediatric Neurology (A.K.), University Children's Hospital Basel, Switzerland; Department of Pediatrics (Pedro de Alarcon), University of Illinois College of Medicine at Peoria, Peoria IL; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard Medical School, MA; Division of Neurology (W.G.M.), Department of Pediatrics, Children's Hospital Los Angeles; and Department of Neurology (W.G.M.), Keck School of Medicine at the University of Southern California, Los Angeles.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
Neurology(R) neuroimmunology & neuroinflammation 2022-03-08
-
Immunotherapy responsive SARS-CoV-2 infection exacerbating opsoclonus myoclonus syndrome.
Multiple sclerosis and related disorders 2021-02-23
Jonathan D Santoro
2 publications dans cette catégorie
Affiliations :
- From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA. jdsantoro@chla.usc.edu.
Publications dans "Syndrome des mouvements périodiques nocturnes des membres" :
-
Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome.
Neurology(R) neuroimmunology & neuroinflammation 2021-09-02
-
Immunotherapy responsive SARS-CoV-2 infection exacerbating opsoclonus myoclonus syndrome.
Multiple sclerosis and related disorders 2021-02-23
Sources (10000 au total)
Educational Attainment and US Drug Overdose Deaths.
Educational attainment in the US is associated with life expectancy. As the opioid crisis worsens, it is critical to understand how overdose death rate trends evolve across education groups.... To investigate the association between educational attainment and overdose death rates, with emphasis on trends during the COVID-19 pandemic.... This cross-sectional study used National Vital Statistics System Mortality Multiple Cause-of-Death data describing overdose death rates in the US by educational attainment from January 1, 2000, to Dec... Educational attainment, categorized as no high school (HS) diploma, HS diploma (or General Educational Development) but no college, some college but no bachelor's degree, and bachelor's degree or more... The main outcomes were rates of all overdose deaths, overdose deaths involving opioids, and overdose deaths involving synthetic opioids.... Of 912 057 overdose deaths with education information from 2000 to 2021 (mean [SD] age at death, 44.9 [12.3] years; 64.1% male), there were 625 400 deaths (68.6%) among individuals with no college edu... In this cross-sectional study, lower educational attainment was found to be associated with higher growth in overdose deaths. As the opioid crisis has transitioned to fentanyl and polysubstance use, o...
Psychological distress and the risk of drug overdose death.
Previous research has shown an association between psychological distress and overdose death among specific populations. However, few studies have examined this relationship in a large US population-b... Data from the 2010-2018 NHIS were linked to mortality data from the National Death Index through 2019. Psychological distress was measured using the Kessler 6 scale. Drug overdose deaths were examined... The study population included 272,561 adults. Adjusting for demographic covariates and using no psychological distress as the reference, distress level was positively associated with the risk of overd... Limited substance use information prevented adjustment for this potentially important covariate.... Adults with psychological distress were at greater risk of drug overdose death, relative to those without psychological distress. Adults with psychological distress were also at increased risk of deat...
Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon.
With the implementation of Measure 110 (M110) in 2021, Oregon became the first US state to decriminalize small amounts of any drug for personal use. To date, no analysis of the association of this law... To evaluate whether the decriminalization of drug possession in Oregon was associated with changes in fatal drug overdose rates after accounting for the rapid spread of fentanyl in Oregon's unregulate... In this cohort study, the association between fatal overdose and enactment of M110 was analyzed using a matrix completion synthetic control method. The control group consisted of the 48 US states and ... Measure 110 took effect in Oregon on February 1, 2021.... The primary outcome assessed was fatal drug overdose rates per half-year. A changepoint analysis also determined when each state experienced a rapid escalation of fentanyl in its unregulated drug mark... In this analysis, rapid spread of fentanyl in Oregon's unregulated drug supply occurred in the first half of 2021, contemporaneous with enactment of M110. A positive crude association was found betwee... In this cohort study of fatal drug overdose and the spread of fentanyl through Oregon's unregulated drug market, no association between M110 and fatal overdose rates was observed. Future evaluations o...
Association of drug overdoses and user characteristics of Canada's national mobile/virtual overdose response hotline: the National Overdose Response Service (NORS).
Several novel overdose response technology interventions, also known as mobile overdose response services (MORS), have emerged as adjunct measures to reduce the harms associated with the drug poisonin... A retrospective analysis was conducted using NORS call logs from December 2020 to April 2023 imputed by operators. A variety of variables were examined including demographics, substance use and route,... Of the 6528 completed calls on the line, 3994 (61.2%) were for supervised drug consumption, 1703 (26.1%) were for mental health support, 354 (5.42%) were for harm reduction education or resources, and... NORS presents a complimentary opportunity to access harm reduction services for individuals that prefer to use alone or face barriers to accessing in-person supervised consumption services especially ...
Estimating Drug Involvement in Fatal Overdoses With Incomplete Information.
Death certificates provide incomplete information on the specific drug categories involved in fatal overdoses. The accuracy of previously developed corrections for this and modifications to them was e... Data were obtained for the universe of 932,364 drug overdoses in the U.S. between 1999 and 2020, including 769,982 (82.6%) with a drug classification and 162,382 (17.4%) without, from the National Cen... Previous regression-based corrections that controlled for decedent characteristics can be improved upon by adding state-fixed effects as covariates. Once this is done, supplementary controls for count... Failing to correct for incomplete information on death certificates leads to inaccurate counts of deaths from specific categories of drugs, such as opioids. However, relatively simple corrections are ...
Estimating the uncertain effect of the COVID pandemic on drug overdoses.
U.S. drug-related overdose deaths and Emergency Department (ED) visits rose in 2020 and again in 2021. Many academic studies and the news media attributed this rise primarily to increased drug use res... We use national data from the Centers for Disease Control and Prevention (CDC) on rolling 12-month drug-related deaths (2015-2021); CDC data on monthly ED visits (2019-September 2020) for EDs in 42 st... Mortality. National overdose mortality increased from 21/100,000 in 2019 to 26/100,000 in 2020 and 30/100,000 in 2021. The rise in mortality began in mid-to-late half of 2019, and the 2020 increase is... The reasons for rising overdose mortality in 2020 and 2021 cannot be definitely determined. We lack a control group and thus cannot assess causation. However, the observed increases can be largely exp...
Years of life lost to drug overdose in the Latinx community during the most recent wave of overdose deaths.
This study estimated years of life lost (YLL) among US Latinx individuals during the most recent wave of drug overdose deaths.... A serial cross-sectional study of YLL (life expectancy minus age at death) from death certificate records of Latinx individuals who died from drug overdoses from 2015 to mid-2022.... Over the study period, 58,209 Latinx individuals aged 15-64 years died from drug overdoses resulting in 2,266,784 YLL. Age-group YLL differences remained stable, but gender YLL trajectories diverged.... This study extends our understanding of the immense loss to Latinx communities from preventable drug deaths....
Self-regulated Anti-Overdose Crush and Extraction-Resistant Drug Delivery System to Combat Opioid Overdose Crisis.
Pharmaceutical opioid dosage forms are commonly misused via an oral route in non-manipulated form, i.e., overdose in intact form, or manipulated form, i.e., after crushing the dosage form, and also vi...
Reducing Drug Overdose Deaths: Significant Changes Needed in U.S. Drug Treatment Policy.
Slow and incremental changes in federal and state drug policies are neither meeting treatment needs nor reversing yearly increases in drug-related mortality. U.S. drug policies convey confounding mess...